Lv1
20 积分 2025-04-30 加入
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
5小时前
求助中
Molecular Pathology of Prostate Cancer
2个月前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
2个月前
已完结
STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer
2个月前
已完结
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
3个月前
已完结
Human epidermal growth factor receptor 2 targeted agents in gynecologic cancers: an updated review
3个月前
已完结
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
Immunotherapy for hepatocellular carcinoma
10个月前
已完结
Endometriosis-associated Serous Borderline Tumor and Endometrial Stromal Sarcoma of the Ovary
11个月前
已完结
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
1年前
已完结
皖公网安备34019202002308
